Intervalo de referencia de testosterona en hombres adultos jóvenes del municipio Plaza de la Revolución

Aimee Álvarez Álvarez, Dashmilia Rivero Giral, Alina Chapé Puertas, Emma Domínguez Alonso, Gilda Monteagudo Peña, Antonio Darwin Reyes Rodríguez, Juan Clemente Abreu, Lucila Hierrezuelo

Texto completo:

PDF XML

Resumen

Introducción: El hipogonadismo masculino puede provocar una reducción importante de la calidad de vida. La determinación de testosterona total constituye la opción inicial para el diagnóstico bioquímico del hipogonadismo. Con este fin resulta necesario definir los intervalos de referencia de esta hormona en los diferentes grupos etarios, en cada laboratorio, población o grupo particular de estudio.

Objetivo: Determinar el intervalo de referencia de testosterona total para la población masculina en edad reproductiva del municipio Plaza de la Revolución.

Métodos: Se realizó un estudio transversal y descriptivo, en una muestra representativa (n=143) de la población masculina entre 20 y 40 años, del municipio Plaza de la Revolución. Para el reclutamiento de la muestra se utilizó un método directo. El intervalo de referencia se estableció mediante un método no paramétrico. Se realizó interrogatorio, examen físico, complementarios bioquímicos (glucemia, colesterol, triglicéridos, HDL-c, LDL-c), hormonales (testosterona total, PRL, FSH y LH). 

Resultados: El promedio de edad fue de 29,7 años. El índice de masa corporal osciló entre 18,95 y 29,88 kg/m2 (valor medio 24,15). Las medias de las circunferencias de cintura y cadera fueron de 86,62 cm y 99,77 cm respectivamente. El intervalo de referencia de testosterona total calculado para la población masculina del municipio Plaza de la Revolución, fue de 7,69 a 40,52 nmol/L. La mediana para la testosterona total fue de 19,10 nmol/L.

Conclusiones: El intervalo de referencia de testosterona total calculado para la población masculina adulta (20 - 40 años) del municipio Plaza de la Revolución difiere del reportado por el fabricante del kit diagnóstico y puede resultar de utilidad en la práctica clínica.

Referencias

T. Hugh Jones. What should I do with a 60-year old man with a slightly low serum total testosterone concentration and normal levels of serum gonadotrophins? Clinical Endocrinology. 2010;72:584–88.

Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.

Morgentaler A, Zitzmann M, Traish AM, Fox A. International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic. Aging Male. 2015;18(4):205-6.

Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–31.

Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Age-associated changes in hypothalamic–pituitary–testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal result from the European Male Ageing Study. Eur J Endocrinol. 2013;168:445-55.

Zangshung L, Jie L, Xiachong S, Wang L, Jang J, Shi X. Dynamic alteration of serum testosterone with aging: a cross - sectional study from Shanghai, China. Reprod Biol Endocrinol. 2015;13:1-7.

Yeap BB. Hormonal Changes and Their Impact on Cognition and Mental Health of Ageing Men. Maturitas 2014;79(2),227-235. DOI: 10.1016/j.maturitas.2014.05.015

Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: The Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47–54

Ebeling PR. Androgens and Osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2010: 17(3):284-92.

Gaffney CG, Pagano MJ, Kuker AP, Stember DS, Stahl PJ. Osteoporosis and low bone mineral density in men with testosterone deficiency syndrome. Sex Med Rev. 2015; 3:298–315.

Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

Deng C, Zhang Z, Li H, Bai P, Cao X, Dobs AS. Analysis of cardiovascular risk factors associated with serum testosterone levels according to the US 2011–2012 National Health and Nutrition Examination Survey, The Aging Male. 2018. DOI: 10.1080/13685538.2018.1479387.

Zarotsky V, Huang M, Carman W, Morgentaler A, Singhal P, Coffin D, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014;2:819–34.

Mushannen T, Cortez P, Stanford FC, Singhal V. Obesity and Hypogonadism—A Narrative Review Highlighting the Need for High-Quality Data in Adolescents. Children. 2019;6:63-84. DOI:10.3390/children6050063.

Fernández M, Chillarón J, Botel J. Deficit de testosterona, síndrome metabólico y diabetes mellitus. Med. Clin. (Barc) 2016;146(2):69-73.

Ebrahimi F, Christ M. Metabolic Syndrome and hypogonadism. Two peas a pod. Swiss Med Wkly. 2016;146:142-83.

Prashant G, Amorin RP. The relation between metabolic syndrome and testosterone level. Rom J Diabetes Nutr Metab Dis. 2018;25(1):109-14.

Bica L, Lezha M, Kuka N, Goda A. Relation of serum testosterone levels to high density lipoprotein cholesterol and triglyceride in men. J Am Coll Cardiol. 2013; 62(18_S2):181-3.

Hamda A, Bouloux PM. Primary hypogonadism. In: Testosterone deficiency in men, edited by T Hugh Jones, Oxford University Press. 2008:37-47.

OH JY, Barrett Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25:56-60.

Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from Massachusetts male aging study. Diabetes Care. 2000;23:490-4.

Rastrelli G, Carter EL, Ahern T, Finn JD, Antonio L, O’Neill TW, et al. EMAS Study Group. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. J Clin Endocrinol Metab. 2015;100(8):3172–3182.

Dean JD, McMahon CG, Guay AT, Morgentaler A, Althof SE, Becher EF, et al. The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone deficiency in adult men. J Sex Med. 2015;12:1660-86.

Rosner W. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405–413.

Campusano C, Brusco F, Campino C, Rodríguez L, Arteaga E. Comparación de distintos métodos para evaluar la función androgénica en el adulto mayor. Rev Med Chile. 2006;134:1123-8.

T Hugh Jones. Diagnosis of hypogonadism: symptoms, signs, tests, and guidelines. In: Testosterone deficiency in men, ed. by T Hugh Jones. Oxford University Press, 2008: 330-6.

Zitzmann M. The role of the CAG repeats androgen receptor polymorphism in andrology. In: Frontiers in Hormone Research, ed. by T.H. Jones; 2009. p 52–61.

Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. CLINICAL RESEARCH ARTICLE. J Clin Endocrinol Metab. 2017,102(4):1161–1173.

doi: 10.1210/jc.2016-2935. https://academic.oup.com/jcem

Fanelli F, Gambineri A, Mezzullo M, Vicennati V, Pelusi C, Pasquali R. Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. Rev Endocr Metab Disord. 2013;14:185–205.

Rosner W, Vesper H; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab. 2010;95(10):4542-8.

Barham D and Trinder P. Glucosa GOD-PAP. Analyst. 1972;97:142-5.

Solberg HE, Stamm D. I. IFCC recommendation: The theory of reference values. Part 4. Control of analytical variation in the production, transfer and application of reference values. J Automat Chem. 1991;13:231-4.

Horns PS, Pesce AJ. Reference intervals: anupdate. Clin Chim Acta. 2003;334:5-23.

CLSI. Defining, establishing and verifying reference intervals in the clinical laboratory; Approved Guidelines-Third Edition by Horowitz G. CLSI document EP28-A3c. Wayne PA; Clinical and Laboratory Standard Institute; 2008;28(30): EP28-A3c. ISBN 1-56238-682-4. ISSN 0273-3099.

Friedrichs KR, Harr KE, Freeman KP, Szladovits B, Walton RM, Barnhart KF, et al. ASVCP reference interval guidelines: determination of de novo reference intervals in veterinary species and other related topics. Vet Clin Pathol. 2012;41:441-453. ISSN 0275-6382. DOI:10.1111/vcp.12006.

Amore M, Innamorati M, Costi S, Sher L, Girardi P, Pompili M. La deficiencia parcial de andrógenos, la depresión, y los suplementos de testosterona en hombres de edad avanzada. Int J Endocr. 2012;(7):280-84.

Tate JR, Koerbin G, Adeli K. Opinion paper: Deriving harmonised reference intervals – global activities. EJIFCC. 2016;27:48–65.

Koerbin G, Tate JR. Harmonising adult reference intervals in Australia and New Zealand – the continuing story. Clin Biochem Rev. 2016;37:121–29.

Berg J. The UK Pathology Harmony initiative; The foundation of a global model. Clin Chim Acta. 2014;432:22–6.

Ozarda Y, Sikaris K, Streichert T, Macri J. On behalf of IFCC Committee on Reference intervals and Decision Limits (C-RIDL). Distinguishing reference intervals and clinical decision limits – A review by the IFCC Committee on Reference Intervals and Decision Limits (C-RIDL). CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES. July 2018 https://doi.org/10.1080/10408363.2018.1482256

Laaksonen DE, Niskanen L, Punnonen K, Nyysonen K, Tuomanen TP. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036-41.

Pitteloud N, Mootha VK, Dwyer AA. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28:1636-42.

Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews Endocrinology. 2013;9:479-493. DOI:10.1038/nrendo.2013.122.

Jalaboyas M, JM, Zaragoza QA, Cortis FC, Zaragoza QA, Salom GM, Nuez ChP. Cambios en las hormonas sexuales en varones mayores de 50 años. Prevalencia de niveles bajos de testosterona y factores de riesgo. Actas urológicas españolas. 2008;32(6):603-10.

Boyce MJ, Baisley KJ, Clark EV, Warrington SJ. Are published normal ranges of serum testosterone too high? Results of a crosssectional survey of serum testosterone and luteinizing hormone in healthy men. BJU Int. 2004;94(6):881–85.

González Sánchez V, Moreno Pérez O, García de Guadiana L, Sánchez Pellicer P, Alfayate R, Mauri M, et al. Reference ranges for serum and salivary testosterone in young men of Mediterranean region. Endocrinol Nutr. 2015;62(1):4 –10.

Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–39.

Morgentaler A, Traish A, Hackett G, Jones TH, Ramasamy R. Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine. Sex Med Rev. 2019;7(4):636–649. pii: S2050-0521(19)30067-8. DOI: 10.1016/j.sxmr.2019.06.003. [Epub ahead of print]

Enlaces refback

  • No hay ningún enlace refback.